I'm LongbridgeAI, I can summarize articles.Germany's Merck KGaA raised its full-year guidance for the second consecutive quarter, citing robust performance and easing currency headwinds. The company now expects net sales of €21 billion to €21.8 billion with organic growth of 1% to 3%, up from previous forecasts. EBITDA excluding one-time items is projected at €5.9 billion to €6.3 billion. Management attributed the upgrade to abating foreign-exchange pressures, stronger demand in life-science and electronics markets, and resilience in healthcare operations.
By Adria Calatayud
Germany's Merck KGaA raised its full-year guidance for the second quarter in a row, citing a robust performance and easing foreign-exchange headwinds.
The German life-sciences and chemicals group said Thursday that it now expects net sales for the full year to range from 21 billion to 21.8 billion euros ($24.26 billion-$25.19 billion), with organic growth of 1% to 3%. It had previously forecast sale to be flat or grow up to 3% organically, resulting in revenue of 20.4 billion to 21.4 billion euros.
The company anticipates earnings before interest, taxes, depreciation and amortization excluding one-time items to be between 5.9 billion and 6.3 billion euros, with growth of up to 3%. This compares with its previous guidance of 5.7 billion to 6.1 billion euros, with an organic performance ranging from a 2% fall to a 2% rise.
Merck, which already lifted its full-year outlook alongside first-quarter results, said this reflected abating foreign-exchange headwinds and expectations of stronger demand in the life-science and electronics markets, together with resilience in its healthcare operations.
"Our second-quarter performance confirms continued momentum from important growth drivers across all the industries we serve," Chief Executive Kai Beckmann said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
August 06, 2026 01:22 ET (05:22 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.